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BACKGROUND. Phytotherapy has been used to treat patients with lower urinary tract
symptoms (LUTS). We evaluated the efficacy and tolerability of combination therapy between
Serenoa Repens (SeR), Lycopene (Ly), and Selenium (Se)þ tamsulosin versus single therapies.
METHODS. PROCOMB trial (ISRCTN78639965) was a randomized double-blinded, double-
dummy multicenter study of 225 patients between 55 and 80 years old, PSA 4 ng/ml, IPSS
12, prostate volume 60 cc, Qmax 15ml/sec, postvoid residual urine (PVR) <150ml.
Participants were randomized group A (SeR-Se-Ly), group B (tamsulosin 0.4mg), group C
(SeR-Se-Lyþ tamsulosin 0.4mg). The primary endpoints of the study were the reduction of
IPSS, PVR, and increase of Qmax in group C versus monotherapy groups.
RESULTS. The decrease for combination therapy was significantly greater versus group A
(P< 0.05) and group B (P< 0.01) for IPSS and versus group A (P< 0.01) for PVR from baseline
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to 6 months. A greater decrease in IPSS was observed for Group C versus group A (P< 0.01)
and increase in Qmax versus group B (P< 0.01), from 6 months to 12 months. At one year, the
changes of IPSS and Qmax were greater for Group C versus monotherapies (each comparison
<0.05). The proportions of men with a decrease of at least three points (each comparison
P< 0.05) and decrease of 25% for IPSS (each comparison P< 0.01) were greater for Group C.
CONCLUSION. SeR-Se-Lyþ tamsulosin therapy is more effective than single therapies in
improving IPSS and increasing Qmax in patients with LUTS. Prostate 74:1471–1480, 2014.
# 2014 Wiley Periodicals, Inc.
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INTRODUCTION
Benign prostatic hyperplasia (BPH) is one of the
most frequent causes of Lower Urinary Tract Symp-
toms (LUTS) in men and about 50% of men between
50 and 60 years suffer from this disease [1]. Even
today, the exact molecular mechanisms underlying
the development and progression of LUTS/BPH have
not been fully understood. Certainly, recent studies
have shown that chronic inflammation represents a
crucial component in the pathogenesis of BPH, proba-
bly determining the hyperplasia of prostate cells. The
inflammatory cells in fact, produce growth factors
such as VEGF or TGF- b, which can support the
fibromuscular growth in BPH [2].
In this context, medical therapy such alpha-blockers
and 5-alpha reductase inhibitors or combination
therapy have been used to relief symptoms and to
prevent complications. The COMBAT and MTOPS
studies have demonstrated the significant benefits of
the combination therapy if compared with individual
mono therapies [3,4]. However, despite the improve-
ment in symptoms, side effects (erectile dysfunction,
ejaculatory disorders, loss of libido) may limit
adherence to treatment. For these reasons, some
phytotherapics, like the lipid extract (LE) of Serenoa
Repens (SeR) are currently used with the aim of
improving symptoms and limiting the possible adverse
effects.
SeR is frequently combined with other compounds
like Selenium (Se) and the carotenoid lycopene (Ly) in
the effort to increase its therapeutic activity in BPH.
Several mechanisms of action have been proposed
to explain their therapeutic effects. The combined
treatment with Se-Ly-SeR has been demonstrated to be
more effective than SeR alone in preventing BPH and
inhibited growth by 83%, suggesting that (Se) and (Ly)
at pharmacological doses further increase Serenoa
repens efficacy in BPH [5].
The LE of SeR would act by inhibiting the 5-alpha
reductase and the binding between the diihydrotestos-
terone and the androgen receptor, antagonizing the
a1- adrenergic receptor, and inhibiting cell proliferation
and the production of COX-2 and 5-leukotrienes [6].
In addition, Ly and Se would act through some
seleno-proteins promoting an optimal balance between
oxidants/antioxidants, with significant beneficial
effects on LUTS/BPH. Although these premises, sever-
al doubts still persist about the efficacy of phytother-
apics in relief BPH/LUTS symptoms insomuch as the
recent EAU and AUA guidelines did not recom-
mended it [1,7].
Recent studies carried out on experimental models
of bladder outlet obstruction, have highlighted how
the combination between SeR, Se, and Ly is more
effective than the single SeR in reducing prostate
inflammation, the expression of growth factors, oxida-
tive stress and prostatic hyperplasia [5,6].
On the basis of these observations, a combination
therapy with alpha-blockers and SeR-Se-Ly certainly
provides a rational pathophysiological, with the aim
of ensuring a high therapeutic efficacy with limited
side effects.
The following multicenter, randomized protocol,
aimed to evaluate the efficacy and tolerability of the
combination therapy between SeR-Se-Lyþ tamsulosin
versus the individual monotherapies with SeR-Se-Ly
or tamsulosin in patients with LUTS/BPH.
MATERIALANDMETHODS
StudyDesign
From March 2011 to March 2012, 225 consecutive
patients from 11 Italian centers were enrolled in this
randomized, double-blinded, double-dummy multi-
center study. The following trial was conducted in
accordance with the ethical principles described in
the Declaration of Helsinki and was approved by the
local Ethical Committee. The present study, named
as PROCOMB trial, is registered under number
ISRCTN78639965.
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Participants
The inclusion criteria were: age between 55 and 80
years old, digital rectal examination negative for
prostate nodules, PSA 4 ng/ml, IPSS 12, prostate
volume 60 cc (assessed by ultrasound), Qmax
15ml/sec, postvoid residual urine <150ml. Exclu-
sion criteria were patients with prostate cancer, previ-
ous bladder cancer, diabetes mellitus, neurogenic
disorders, severe liver disease, history of orthostatic
hypotension or syncope, symptomatic urinary tract
infection, anti-androgens, antidepressants (neurolep-
tics, anti cholinergics) therapy, recent treatment with
an a blocker (within 1 month) or phytotherapy includ-
ing saw palmetto extract (within 3 months), previous
medical therapy with 5-ARI or surgical treatment for
LUTS/BPH, patients with catheter or with an episode
of acute retention of urine in the last 4 weeks.
After screening and possible pharmacological
wash-out, the participants were off-site central ran-
domized with a 1:1:1 ratio into three treatment arms
each consisting of 75 patients.
Intervention
During double-blind treatment, patient received
SeR-Se-Lyþplacebo for one year (Group A), tamsulo-
sin 0.4mgþplacebo for one year (Group B), or
SeR-Se-Lyþ tamsulosin 0.4mg for one year. Identical
tablets were used to ensure that the blinded regimen
was identical for all treatment groups.
Outcomes
The main outcome measures included IPSS, IPSS
quality-of -life (QoL), IIEF-5, Qmax measured at
uroflowmetry, post-void residual (PVR) and Ejacula-
tion Questionnaire (EjQ), performed at enrollment
(visit one), 1 month (visit two), at 3 months (visit
three), at 6 months (visit four) and 12 months (visit
five).
The Ejaculation questionnaire (EjQ) was based on
the following scores: one¼ orgasm with a reduction in
the strength of the semen, two¼ orgasm with a
reduced amount of semen, three¼ orgasm without
emission of semen, four¼no orgasm.
The evaluation of the prostate volume by transrectal
ultrasonography and Prostate Specific Antigen (PSA)
tests were performed at visit one, visit four, and visit
five.
The uroflowmetry was conducted with valid mea-
surement of Qmax required a bladder filling measured
150 and 550ml and a voided volume 125ml.
Safety data were evaluated collecting adverse events
(AEs). Treatment-related adverse events (TEAEs) were
considered those reported for the first or worsened
after randomization.
The primary endpoints of the study were the
reduction of IPSS, increase of Qmax and the reduction
of PVR in patients treated with combination therapy
compared to single monotherapies after 1 year. We
also evaluated the proportion of men with a decrease
of at least three points and decrease of 25% for IPSS
and with an increase of 30% of Qmax. Secondary
endpoints of the study were considered the change in
erectile function (assessed by the International Index
of Erectile Function-5 questionnaire), prostate volume,
serum PSA and QoL at 1 year.
One tablet of Profluss1 consisted of 320mg of
supercritical CO2 lipidic extract SeR containing 85% of
fatty acids sterols, selenium (50mcg) and lycopene
(5mg) (Ayanda AS, Norway) and distributed by
Konpharma Srl (Rome, Italy).
Statistical Analysis
This randomized clinical trial was designed to
enroll 75 patients for group (assuming a 10% drop-
outs) using one-sided of a level of 0.05 with 90%
power and assuming that the differences were as-
sumed to be >2 with a standard deviation of four
between the means of last IPSS of arm C versus B or A.
The patients enrolled were sufficient to evaluate the
differences between arm C and B or arm C and A, in
term of Q-max, using one-sided of a level of 0.05 with
90% power and assuming that differences were as-
sumed to be >2 with a standard deviation of four.
The sample size was estimated based on the previ-
ous study [8]. The Mann-Whitney U Test was used for
comparisons in the distribution of non-normal varia-
bles between a pair of treatment. The efficacy variables
were tested as change from visit one to visit four, from
four to five relative to primary endpoints and from
baseline to visit five relative to primary and secondary
endpoints. Qualitative outcome were tested using the
Chi -Square Test (x2 -Test) and z-test was used
comparison of different between two proportion. A
two sided P-value <0.05 was considered statistically
significant in all the tests used. The rank analysis of
covariance was used to evaluate the influence of
difference value at the baseline.
RESULTS
Of all patients randomized, 219 have completed the
12 months of treatment (Fig. 1). Table I shows the
baseline characteristics of the patients enrolled. Treat-
ment groups were well balanced with regard to demo-
graphic and clinical characteristics at baseline. Of all
subjects, median age was 65 years (range: 55–79),
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Fig. 1. Dispositionof subjects. SubjectConsolidatedStandardsofReportingTrials (CONSORT)diagram.
TABLEI. Baseline Characteristics of the Patients.
Group A Serenoa repens,
lycopene and selenio (n¼ 67)
Group B Tamsulosin
(n¼ 78)
Group C Serenoa repens,
lycopene and selenioþ
tamsulosin (n¼ 74)
Age, median (range) 65 (55–79) 66 (56–79) 65 (56–76)
PSA (ng/ml/), median (range) 1.94 (0.15–4.0) 2.11 (0.14–4) 2.11 (0.38–3.87)
Prostate Volume (cc), median (range) 43 (17–60) 45 (20–60) 45 (20–60)
Qmax (ml/sec), median (range) 12 (5.4–15) 11.8 (4–15) 12.0 (6–15)
PVR (ml), median (range) 45 (0–130) 50 (0–140) 60 (0–140)
IPSS, median (range) 18 (12–35) 19 (12–33) 20 (12–35)
IIEF-5, median (range) 19 (1–25) 18 (1–25) 17 (1–25)
EjQ, median (range) 2 (1–3) 2 (0-3) 2 (0–3)
QoL, median (range) 3 (0–5) 4 (1–6) 3 (1–6)
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median PSA was 2.1ng/ml (range: 0.14–4), median
Qmax was 11.8 (range: 4–15), median prostate volume
was 43 cc (range: 17–60), median IPSS was 19 (range:
12–35), and median PVRwas 50 cc (range: 0–140) (Table I).
Figure 1 shows the variation of primary end-points
in the three groups of treatment. The decrease for
combination therapy was significantly greater versus
group A (P< 0.05) and group B (P< 0.01) in terms of
IPSS and verses group A (P< 0.01) in terms of PVR
from baseline to 6 months.
From 6 months to 12 months, Qmax significantly
changed in Group C (P< 0.01) and PVR significantly
changed in group B (P< 0.01). A significantly greater
decrease in IPSS was observed for combination thera-
py versus group A (P< 0.01) and increase in Qmax
versus group B (P< 0.01), from 6 months to 12 months.
At 1 year, the median change of IPSS and of Qmax
were significantly greater for combination therapy
versus that of either monotherapy (each comparison
<0.05). A significantly greater decrease in PVR was
observed for combination therapy versus Group A
(P< 0.05) at 12 months (Table II; Fig. 2).
The percentage change of IPSS was significantly
greater for combination therapy versus tamsulosin
(18.2% vs. 13.8%, P< 0.05) and versus SeR-Se-Ly
(18.2% vs. 14.3%, P< 0.05).
TABLEII. Primary and Secondary End-PointsVariations inGroupA,B andC.
Group A Serenoa repens,
lycopene and selenio
(n¼ 67)
Group B Tamsulosin
(n¼ 78)
Group C Serenoa repens,
lycopene and selenio þ
tamsulosin (n¼ 74)
IPSS
Median (range) change from baseline 3.0 (13 to 3.0) 3.0 (20 to 8.0) 4.0 (17 to 5.0)
Median (range) change versus. group A — 0 (0.9 to 1.0) 2.0 (3 to 1)§
Median (range) change versus. group B — — 2.0 (3 to 1)§
Qmax, ml/sec
Median (range) from baseline 2.0 (5,3; 11) 2.0 (8; 15) 2.3 (3; 13)
Median (range) change versus. group A — 0.1 (1.0 to 0.8) 1 (0.001 to 2)
Median (range) change versus. group B — — 0.8 (0.1 to 1.7)
Post-void residue, ml
Median (range) change from baseline 10.0 (70; 90) 30.0 (100; 80) 34.5 (112; 100)
Median (range) change versus. group A — 18.0 (10.0 to 24.99)§ 20.0 (30.0 to 10.0)§
Median (range) change versus. group B — — 5.0 (15.0 to 5)
IIEF-5
Median (range) change from baseline 0.3 (19.0 to 8.0) 0.2 (5.0 to 4.0) 0.7 (4.0 to 11.0)
Median (range) change versus. group A — 0.0 (1.0 to 1.0) 0 (1.0 to 1.0)
Median (range) change versus. group B — — 1 (0 to 1.0)§
EjQ
Median (range) change from baseline 0.22 (3.0 to 1.0) 0.27 (2.0 to 3.0) 0.36 (2.0 to 2.0)
Median (range) change from baseline — 0.0 (0.1 to 0.1) 0 (0.1 to 0.1)
Median (range) change from baseline — — 0 (0.1 to 0.1)
QoL
Median (range) change from baseline 1 (4; 3) 1 (5; 2) 1 (5; 3)
Median (range) change versus. group A — 0.0 (0.1 to 0.1) 0 (0.1 to 1.0)
Median (range) change versus. group B — — 0 (0.1 to 1.0)
PSA, ng/ml
Median (range) change from baseline 0 (1.40; 2.20) 0.09 (2.5; 3.13) 0.16 (1.74; 2.55)
Median (range) change versus. group A — 0.1 (0.8 to 0.3 0.16 (0.1 to 0.35)z
Median (range) change versus. group B — — 0.08 (0.1 to 0.22)
Prostate Volume, cc
Median (range) change from baseline 1.5 (14; 20) 1.0 (16; 12) 2.5 (15; 20)
Median (range) change versus. group A — 0.0 (1.0 to 2.0) 1 (0.1 to 2.9)
Median (range) change versus group B — — 1 (0.1 to 2.1)
IPSS¼ International Prostate Symptoms Score; IIEF-5¼ International Index of Erectile Function; EjQ¼Ejaculation Questionnaire;
QoL¼Quality of Life.
P< 0.05.
§P< 0.01.
z
one-sided <0.05.
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The percentage increase§ of Qmax for the Group C
was greater versus Group A (24.0 vs. 15.4, P< 0.05)
but not versus Group B (24.0 vs. 17.4, P¼ 0.15).
The proportions of men with a decrease of at least
three points (each comparison P< 0.05) and decrease
of 25% for IPSS (each comparison P< 0.01) were
greater for combination therapy versus that of either
monotherapy. The proportion of men with an increase
of at least 3ml/sec and of 30% of Qmax was not
statistically different for combination therapy versus
single monotherapies (Fig. 3).
Secondary Endpoints
In group C significant differences were demonstrat-
ed in terms of IIEF-5 between baseline and 12 months
(P¼ 0.032). The QoL significantly varied in all treat-
ment groups (P< 0.001). A significantly greater in-
crease in IIEF-5 was observed for combination therapy
versus group B (P< 0.01) and decrease of serum PSA
(P¼ 0.03) at 12 months. No significant differences
were observed in term of EjQ between groups.
There were no significant differences in terms of
TEAEs between the groups (P¼ 0.67). One patient
(1.4%) in group A drop-out for worsening of LUTS.
No dropout occurred in group B and C because of any
drug-related side effects. During the entire study, there
was no evidence of significant variations with regard
to laboratory parameters or vital signs.
Post-hocAnalysis
We performed a post-hoc analysis in patients suffer-
ing from erectile dysfunction (ED) at baseline (IIEF-5
Fig. 2. Median differences of IPSS (A),Qmax (B), and PVR (C) from baseline to 6 and12 months in group A (SeR-Se-Ly), B (Tamsulosin),
and C (Combination). Indicates combination versus tamsulosin two-sided P< 0.05 at 6 months. yIndicates combination versus SeR-Se-Ly
two-sided P< 0.05 at 6 months. §Indicates combination versus tamsulosin two-sided P< 0.05 from 6 to12months. #Indicates combination
versus SeR-Se-Ly two-sided P< 0.05 from 6 to 12 months. Indicates combination versus tamsulosin two-sided P< 0.05 at 12 months.
zIndicatescombinationversusSeR-Se-Ly two-sidedP< 0.05at12months.
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21). One hundred seventy (77.62%) patients had ED at
the time of enrolment: 53 (79.10%) patients in group A,
58 (73.41%) in group B, 59 (78.66%) patients in
group C. The median of the IIEF-5 was 17 (range1–21)
in group A, 17 (range1–21) and 16 (range1–21) in
group C. After 12 months of therapy, 16 (9.4%) of 170
patients do not exhibit ED: 8 (15.1%) in group A, two
(3.4%) in group B, and six (10.2%) in group C. At the
intergroup analysis between group A and group B, it
was found a significant difference about the presence
or the absence of ED post therapy (P¼ 0.046), while any
difference between group A and C (P¼ 0.57) and
between group B and C (P¼ 0.27).
DISCUSSION
SeR has been generally used for the improvement of
symptoms in patients of LUTS/BPH. However, the
scientific community still remain skeptics about its
mechanisms of action or its therapeutic value. In this
context, several clinical trials in the past have com-
pared tamsulosin versus SeR therapy demonstrating a
similar efficacy in reducing LUTS/BPH symptoms
[9,10].
However, the recent European guidelines do not
express a scientific opinion just because of the men-
tioned above bias [1]. Furthermore, a recent meta-
analysis reported that SeR therapy does not improve
LUTS or Qmax compared with placebo in men with
clinical BPH, even at double and triple the usual dose
[11].
Recent studies have proposed a triple combination
between SeR and other essential trace elements like
Selenium (SE) and the carotenoid lycopene (Ly) in the
effort to increase its therapeutic activity in prostatic
diseases. The rationale of this triple therapeutic ap-
proach could be the greater and the enhanced anti-
inflammatory activity [6].
In this multicenter, randomized, double-blinded
study, it has been evaluated for the first time the
efficacy and the tolerability of the combination therapy
with SeR-Se-Lyþ tamsulosin 0.4mg versus the indi-
vidual monotherapies in patients with moderate-se-
vere LUTS/BPH after 1 year of follow-up.
First of all we should noticed that after 6 months of
treatment, combination therapy significantly improve
symptom score compared with single therapy, while it
was not demonstrated statistical superiority in term of
Qmax. Interestingly, from 6 to 12 months, combination
therapy demonstrated significant changes over tamsu-
losin group in term of Qmax.
In relation to the analysis of the primary endpoints,
the combination therapy has been demonstrated to be
more effective than the individual monotherapies in
terms of reduction of the IPSS and of increase of Qmax
after 1 year.
Indeed, the combination therapy resulted in a
decrease of at least 3 points of the IPSS in 72% of cases,
Fig. 3. Proportionofpatientswithimprovementof IPSS andQmax. Indicates two-sidedP< 0.05versus combination. yIndicates two-sided
P< 0.01versuscombination.
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in a reduction of 25% of the IPSS in 45% with
significant advantages over each single therapy. Unfor-
tunately, literature data on combination therapy are
lacking.
In a retrospective study of 100 patients Argirovic of
2009, the addition of SeR to tamsulosin did not have
any clinical benefit, such as a change in IPSS, Qmax or
PVR[12].
A study published on 2009 by Hizli et al. evaluated
the efficacy of combination therapy with SeR 320mgþ
Tam or the individual monotherapies and no differ-
ence has been found between the treatment arms after
6 months of therapy in terms of IPSS and Qmax.
However, even in this case no data are reported about
the extraction of SeR, nor the power of the study [10].
Furthermore, the heterogeneity of the studies, the lack
of long follow-up and of placebo and especially the
diverse extraction of SeR still limit the correct interpre-
tation about the effectiveness of SeR itself versus
alpha-blocker [11].
It should be taken into account that the results from
MTOPS and COMBAT studies showed considerable
advantages of combination therapy with alpha-block-
ers and 5-ARI against individual monotherapies in
patients suffering from LUTS/BPH [3,4].
In fact, the combination of these pharmacological
classes allows the patient to benefit from each drug,
potentially maximizing the therapeutic response.
In addition, a sub -analysis of the study REDUCE
(Reduction by Dutasteride of Prostate Cancer Events)
has demonstrated the association between BPH and
chronic prostate inflammation in 77% of cases in
patients undergoing prostate biopsy. In addition, this
study also demonstrated a statistically and clinically
significant association between chronic prostatic in-
flammation and severity of LUTS, especially for the
voiding symptoms [13–15].
In a further sub-analysis of the MTOPS study,
Roehrborn et al. emphasized the role of chronic
inflammation on the progression of BPH. In their
study, inflammation was associated with a higher
prostate volume and higher PSA values. Interestingly,
patients with inflammation were at higher risk of
experiencing an episode of AUR compared to those
without inflammation (5.6% vs. 0% respectively,
P¼ 0.003) [16].
To this regard, the anti-inflammatory effect on the
prostate tissue potentially exhibited by LE of SeR was
previously demonstrated by Navarrete et al. who
reported a significant reduction in the levels of
interleukin- 1 and TNF-a after 3 months of treatment
with SeR compared to placebo [17]. More recently,
Latil et al. have demonstrated that the LE of SeR
inhibits the expression of two inflammatory mediators,
the MCP-1/CCL2 and VCAM-1 [18]. Moreover, in a
recent study on experimental models of bladder outlet
obstruction, the combination of SeR-Se-Ly has proved
to be more effective than the single SeR in reducing
prostate inflammation, expression of growth factors,
oxidative stress, and BPH. The inhibition of prostate
growth induced by the SeR-Se-Ly is probably induced
by increase of caspase-9, pro-apoptotic Bax, and reduc-
tion of anti-apoptotic Bcl- 2 [2,5,6,14]. Furthermore
among the three compounds, Ly appears to give the
major contribution in maximizing the effects of SeR-
Se-Ly which induced activation of the programmed
cell death [14].
All these mechanisms suggest that the addition of
SeR-Se-Ly to tamsulosin may give rise to significant
improvements of both LUTS symptoms and the
urinary flow. This combination therapy may maximize
the effects of each drug class, tamsulosin through the
blockage of the a1- adrenergic receptor and the SeR-
Se-Ly through anti-inflammatories and pro-apoptotics
properties [19].
Finally, as reported in the literature, patients with
BPH and chronic inflammation, not only have a higher
risk of disease progression, but also lower rates of
response to medical therapy [20,21].
Of course, the only accurate procedure to diagnose
the presence of chronic inflammation of the prostate is
the prostate biopsy. However it cannot be offered to all
patients, but some less invasive remedies, such evalua-
tion of severity of LUTS, serum PSA, and poor
response to medical treatment, may help to identify
patients with chronic prostate inflammation and risk
of progression [22].
In this context, one may suppose to use combina-
tion therapy with SeR-Se-Ly and tamsulosin really in
subjects with moderate LUTS/BPH and with chronic
inflammation of the prostate, in order to optimize the
benefits of both drugs.
Based on our results, the benefits of combination
therapy appeared just after 6 months for symptoms
and also of Qmax from 6 to 12 months.
In addition to these important considerations, sev-
eral prospective studies have recently confirmed the
close association between LUTS and ED [23], and
the correlation between the severity of LUTS and the
prevalence of ED [24]. About 77% of patients suffered
from ED at the time of enrolment, confirming the strict
relationship between LUTS and ED.
Interestingly, we found that combination therapy
had significantly greater increase of IIEF-5 score
compared to tamsulosin alone (P¼ 0.01). Our findings
in terms of improvement of erectile function may be
explained by the greater reduction in symptoms in the
group treated with the combination therapy, and
the possible reduction in the cellular infiltrate of
inflammatory cytokines.
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However, in the post-hoc analysis, only group A
exhibit superiority over group B (P¼ 0.046). The lack
of significance of combination therapy over tamsulosin
alone, in term of absence of ED after therapy, may be
explained by the greater LUTS improvement of these
groups over group A. To this regards, we do not
suggest to speculate about the possible efficacy of
combination therapy in improving ED in patients with
IIEF-5 21.
Finally, it also should underline the lack of superior-
ity of combination therapy versus each single therapy
relative to the EjQ. This finding may be explained
by the use of a not-validated characteristics of this
questionnaire rather than the real differences between
groups. Of course, our study is not avoided by some
limitations. The small sample size should be taken into
consideration. However, as shown by the determina-
tion of the power of the study, this sample size has
guaranteed a study power of 90%, able to detect a
reduction of at least two points of the IPSS and an
increase of at least two points of Qmax. In fact, the
lack of significance of proportion of men with increase
of at least of 3ml/sec and 30% of Qmax may be related
to the small sample size. Finally the strengths of this
study are the restrict criteria entry and that we
demonstrated for the first time the greater efficacy of
combination therapy with SeR-Se-Lyþ tamsulosin in
patients with LUTS/BPH after 1 year in term of
improvement of symptom score and peak flow.
CONCLUSIONS
Combination therapy with SeR-Se-Lyþ tamsulosin
in for 1year was demonstrated to be more effective
than the single monotherapies by improving IPSS and
slightly Qmax in patients suffering from moderate-
severe LUTS/BPH.
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